1. **Rouet F, et al**. 2007. Usefulness of the Agence Nationale de Recherches sur le SIDA second-generation terminal repeat-based real-time reverse polymerase chain reaction tests.
   J. Acquir. Immune. Defic. Syndr. **45(4):**380-388.

2. **Steegen K, et al.** 2007. Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited setting.
   J. Virol. Methods **146:**178-187.

3. **Rouet F, et al.** 2008. In-house HIV-1 RNA real-time RT-PCR assays: principle, available tests and usefulness in developing countries.
   Expert Rev. Mol. Diagn. **8(5):** 635-650.

4. **Isaakidis P, et al**. 2010. High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia.
   J. Int. AIDS Soc. **13(11):**1-10.

5. **Kesho Bora Study Group.** 2010. Eighteen-month follow up of HIV-1– infected mothers and their children enrolled in the Kesho Bora Study Observational Cohorts.
   J. Acquir. Immune. Defic. Syndr. **54(5):**533-541.

6. **Monleau M, et al.** 2010. Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping.
   J. Antimicrob. Chemother. **65 (8) :**1562-1566.

7. **Rouet F, et al.** 2010. Comparaison of the Generic HIV Viral Load® assay with the amplicor™ HIV-1 Monitor v1.5 and Nuclisens HIV-1 EasyQ® v1.2 techniques for plasma HIV-1 RNA quantitation of non B subtypes: The Kesho Bora preparatory study.
   J. Virol. Methods **163**:253-257.

8. **Segeral O, et al.** 2010. Simplified assessment of antiretroviral adherence and prediction of virological efficacy in HIV-infected patients in Cambodia.
   AIDS Res. Treat. doi: 10.1155/2010/142076.

9. **Stevens WS, et al.** 2010. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings.
   J. Infect. Dis. **201: S**16-S26.

10. **Viljoen J, et al.** 2010. Dried blood spot HIV-1 RNA quantification using open real-time systems in South Africa and Burkina Faso.
    J. Acquir. Immune. Defic. Syndr. **55(3):**290-298.

11. **Blanc FX, et al.** 2011. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.
    N. Engl. J . Med. **365(16):**1471-1481.

12. **Dagnra AY, et al**. 2011. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.
J. Int. AIDS Soc. **14(30):** 1-6.

13. **Huong DTM et al**. 2011. Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam.
Int. J. STD AIDS **22:**659-664.

14. **Kesho Bora Study Group.** 2011. Triple antiretroviral compared with zidovudine and single-dose nevirapine profilaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
Lancet. Infect. Dis. **11:**171-180.

15. **Njom Nlend AE, et al.** 2011. Virological profile of pregnant HIV positive women with high levels of CD4 count in low income settings : Can viral load help as eligibility criteria for maternal triple ARV prophylaxis (WHO 2010 option B ?).
Pan Afr Med J. **10(27):**1-4.

16. **Rouet F, et al.** 2011. Current challenges to viral load testing in the context of emerging genetic diversity of HIV-1.
Expert Opin. Med. Diagn. 5(3):183-202**..**

17. **Tejiokem MC, et al**. 2011. Feasibility of early infant diagnosis of HIV in resource-limited settings: the ANRS 12140-PEDIACAM study in Cameroon.
PloS one **6(7):** e21840.

18. **Trinh TT, et al**. 2011. HIV supression among patients on treatment in Vietnam: a review of HIV Viral Load testing in a public urban clinic in Ho Chi Minh City.
AIDS Res. Treat. **doi :10.1155/2011/230953.**

19. **Kesho Bora Study Group.** 2012. Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs Zidovudine/Single-Dose Nevirapine prophylaxis) : The Kesho Bora Randomized Controlled Trial.
Clin. Infect. Dis. **55(3):**449-460.

20. **Liégois F, at al.** 2012. Suitability of an open automated nucleic acid extractor for high-throughput plasma HIV-1 RNA quantitation in Gabon (Central Africa).
J. Virol. Methods **179:**268-271

21. **Nagot N, et al.** 2012. Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.
BMC Infect. Dis. **12(246):**1-11.

22. **Paboriboune P, et al.** 2012. HIV Viral Load testing in Laos.
Field Actions Science Reports **5:**1-5.
Available online at http://factsreports.revues.org/2628.

23. **Péré H, et al.** 2012. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.AIDS Res. Hum. Retroviruses **28(4):** 315-323.

24. **Sàez-Ciriòn A, et al.** 2013. Post-treatment HIV-1 controllers with a long term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study.
PLoS Pathog. **9(3):** e1003211.

25. **Yapo V, et al.** 2013. Evaluation of dried blood spot diagnosis using HIV1-DNA and HIV1-RNA Biocentric assays in infants in Abidjan, Côte d'Ivoire. The Pedi-Test DBS ANRS 12183.
J. Virol. Methods **193**:439-445.

26. **Chersich MF et al.** 2014. Effect of hazardous and harmful alcohol use on HIV incidence and sexual behaviour: a cohort study of Kenyan female sex workers.
Global. Health **10**(22)
Available online at http://www.globalizationandhealth.com/content/10/1/22

27. **Kamangu EN, et al.** 2014.
Implementation of an in-house quantitative real-time PCR for determination of HIV viral load in Kinshasa.
Open Access Library Journal **1:**e855
Available online at http://dx.doi.org/10.4236/oalib.1100855